Skip to content

Effect of a Plant Rich Diet on in People With Type 2 Diabetes and Obesity

Effect of a Nutrient Dense Plant Rich Diet on Glycemic Control in People With Type 2 Diabetes and Obesity

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02977039
Enrollment
0
Registered
2016-11-30
Start date
2019-11-30
Completion date
2020-06-30
Last updated
2020-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus in Obese

Brief summary

The purpose of this study is to evaluate the effect of a nutrient dense plant rich (NDPR) diet compared to a standard USDA diet on glycemic control, inflammation, and cardiovascular risk in individuals with type 2 diabetes and overweight/obesity.

Interventions

OTHERNDPR diet

nutrient rich plant based diert

OTHERUSDA healthy eating diet

DASH diet

Sponsors

Beth Israel Deaconess Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1. Men and women ages 18-75 2. Type 2 diabetes mellitus diagnosed \> 6 months prior to screening visit according to American Diabetes Association criteria 3. HBA1c \>7.5% but \< 10% 4. BMI \>25 kg/m2 ; \>23 kg/m2 for Asian subjects but \< 45 kg/m2 5. Stable weight (variation \< 5 kg within 6 months of screening visit) 6. Ability to give informed consent 7. Ability to follow verbal and written instructions in English

Exclusion criteria

1. Active cardiac issues: history of myocardial infarction within 3 months of screening visit, unstable angina pectoris, or Class III or Class IV congestive heart failure 2. Persistent uncontrolled hypertension (BP \> 160/100 mmHg on or off antihypertensive medication) 3. Active marijuana or intravenous drug use 4. Recent weight loss (\> 5 kg within 6 months of the screening visit) 5. Inflammatory or irritable bowel disease (Crohn's Disease, Ulcerative Colitis, or IBS) 6. Celiac disease 7. Malignancy treated with chemotherapy within the past 1 year 8. Depression or psychosis requiring hospitalization within 1 year, or use of major antipsychotic or tranquilizer drugs (i.e. benzodiazepines) 9. Renal insufficiency (creatinine clearance \< 30 ml/min) 10. Transaminases \> 2x above the normal range 11. Pregnancy within 6 months of the screening visit 12. Lactation 13. History of surgery for the treatment of obesity (gastric banding, gastric bypass, gastric stapling 14. History of alcohol abuse within the past 5 years 15. Vegetarian/Vegan diet 16. Dairy Allergy/Intolerance 17. Anemia, including iron deficient and megaloblastic 18. Vitamin B12 deficiency 19. Leber's disease

Design outcomes

Primary

MeasureTime frameDescription
Glycemic controlchange at 1, 3, 6, 9, 12 monthsA1C and finger stick blood sugar levels

Secondary

MeasureTime frameDescription
body weightchange at 1, 3, 6, 9, 12 months
body compositionchange at 1,3,6,9, 12 monthsDXA scan
hepatic steatosisbaseline, 1, 3, 6, 9, 12 monthsMRspectroscopy
inflammatory markerschange at, 1, 3, 6, 9, 12 monthsserum inflammatory markers
quality of lifechange at, 1, 3, 6, 9, 12 monthsvalidated questionnaired

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026